{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:09:09Z","timestamp":1791857349714,"version":"4.3.4"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11033-025-10485-4","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T13:31:34Z","timestamp":1744119094000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Transthyretin as a therapeutic target: the future of disease-modifying therapies for Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"52","author":[{"given":"Swetaleena","family":"Shaw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratyush","family":"Porel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2450-2975","authenticated-orcid":false,"given":"Khadga Raj","family":"Aran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"issue":"1","key":"10485_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41572-021-00269-y","volume":"7","author":"DS Knopman","year":"2021","unstructured":"Knopman DS, Amieva H, Petersen RC, Ch\u00e9telat G, Holtzman DM, Hyman BT, Nixon RA, Jones DT (2021) Alzheimer disease. Nat Rev Dis Prim 7(1):33. https:\/\/doi.org\/10.1038\/s41572-021-00269-y","journal-title":"Nat Rev Dis Prim"},{"issue":"10","key":"10485_CR2","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.ajpath.2022.07.002","volume":"192","author":"G Plascencia-Villa","year":"2022","unstructured":"Plascencia-Villa G, Perry G (2022) Neuropathologic changes provide insights into key mechanisms of Alzheimer\u2019s disease and related dementia. Am J Pathol 192(10):1340\u20131346. https:\/\/doi.org\/10.1016\/j.ajpath.2022.07.002","journal-title":"Am J Pathol"},{"issue":"8","key":"10485_CR3","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.3390\/biomedicines10081906","volume":"10","author":"C Sanguinetti","year":"2022","unstructured":"Sanguinetti C, Minniti M, Susini V, Caponi L, Panichella G, Castiglione V, Aimo A, Emdin M, Vergaro G, Franzini M (2022) The journey of human transthyretin: synthesis, structure stability, and catabolism. Biomedicines 10(8):1906. https:\/\/doi.org\/10.3390\/biomedicines10081906","journal-title":"Biomedicines"},{"issue":"4","key":"10485_CR4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/13506120802525285","volume":"15","author":"J Buxbaum","year":"2008","unstructured":"Buxbaum J, Koziol J, Connors LH (2008) Serum transthyretin levels in senile systemic amyloidosis: effects of age, gender and ethnicity. Amyloid 15(4):255\u2013261. https:\/\/doi.org\/10.1080\/13506120802525285","journal-title":"Amyloid"},{"key":"10485_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-021-00883-8","volume":"13","author":"T Gi\u00e3o","year":"2021","unstructured":"Gi\u00e3o T, Saavedra J, Vieira JR, Pinto MT, Arsequell G, Cardoso I (2021) Neuroprotection in early stages of Alzheimer\u2019s disease is promoted by transthyretin angiogenic properties. Alzheimer\u2019s Res Ther 13:1\u20134. https:\/\/doi.org\/10.1186\/s13195-021-00883-8","journal-title":"Alzheimer's Res Ther"},{"key":"10485_CR6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/ana.24725","volume":"80","author":"AJ Loavenbruck","year":"2016","unstructured":"Loavenbruck AJ, Singer W, Mauermann ML, Sandroni P, Dyck BPJ, Gertz M, Klein CJ, Low PA (2016) Transthyretin amyloid neuropathy has earlier neural involvement but better prognosis than primary amyloid counterpart: an answer to the paradox? Ann Neurol 80:401\u201311. https:\/\/doi.org\/10.1002\/ana.24725","journal-title":"Ann Neurol"},{"issue":"41","key":"10485_CR7","doi-asserted-by":"publisher","first-page":"14015","DOI":"10.1074\/jbc.RA120.013440","volume":"295","author":"Q Cao","year":"2020","unstructured":"Cao Q, Anderson DH, Liang WY, Chou J, Saelices L (2020) The inhibition of cellular toxicity of amyloid-\u03b2 by dissociated transthyretin. J Biol Chem 295(41):14015\u201314024. https:\/\/doi.org\/10.1074\/jbc.RA120.013440","journal-title":"J Biol Chem"},{"issue":"14","key":"10485_CR8","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3389\/fnins.2020.00875","volume":"26","author":"P Vancamp","year":"2020","unstructured":"Vancamp P, Butruille L, Demeneix BA, Remaud S (2020) Thyroid hormone and neural stem cells: repair potential following brain and spinal cord injury. Front Neurosci 26(14):875. https:\/\/doi.org\/10.3389\/fnins.2020.00875","journal-title":"Front Neurosci"},{"key":"10485_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/DNND.S452009","volume":"31","author":"PN Tripathi","year":"2024","unstructured":"Tripathi PN, Lodhi A, Rai SN, Nandi NK, Dumoga S, Yadav P, Tiwari AK, Singh SK, El-Shorbagi AN, Chaudhary S (2024) Review of pharmacotherapeutic targets in Alzheimer\u2019s disease and its management using traditional medicinal plants. Degener Neurol Neuromusc Dis 31:47\u201374. https:\/\/doi.org\/10.2147\/DNND.S452009","journal-title":"Degener Neurol Neuromusc Dis"},{"key":"10485_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2147\/DNND.S445130","volume":"31","author":"M Singh","year":"2024","unstructured":"Singh M, Agarwal V, Pancham P, Jindal D, Agarwal S, Rai SN, Singh SK, Gupta V (2024) A comprehensive review and androgen deprivation therapy and its impact on Alzheimer\u2019s disease risk in older men with prostate cancer. Degener Neurol Neuromusc Dis 31:33\u201346. https:\/\/doi.org\/10.2147\/DNND.S445130","journal-title":"Degener Neurol Neuromusc Dis"},{"issue":"3","key":"10485_CR11","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1006\/jmbi.2000.4078","volume":"302","author":"A H\u00f6rnberg","year":"2000","unstructured":"H\u00f6rnberg A, Eneqvist T, Olofsson A, Lundgren E, Sauer-Eriksson AE (2000) A comparative analysis of 23 structures of the amyloidogenic protein transthyretin. J Mol Biol 302(3):649\u2013669. https:\/\/doi.org\/10.1006\/jmbi.2000.4078","journal-title":"J Mol Biol"},{"issue":"258","key":"10485_CR12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0074-7696(07)58003-4","volume":"1","author":"SJ Richardson","year":"2007","unstructured":"Richardson SJ (2007) Cell and molecular biology of transthyretin and thyroid hormones. Int Rev Cytol 1(258):137\u2013193. https:\/\/doi.org\/10.1016\/S0074-7696(07)58003-4","journal-title":"Int Rev Cytol"},{"issue":"6","key":"10485_CR13","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.3390\/ijms21062075","volume":"21","author":"T Gi\u00e3o","year":"2020","unstructured":"Gi\u00e3o T, Saavedra J, Cotrina E, Quintana J, Llop J, Arsequell G, Cardoso I (2020) Undiscovered roles for transthyretin: from a transporter protein to a new therapeutic target for Alzheimer\u2019s disease. Int J Mol Sci 21(6):2075. https:\/\/doi.org\/10.3390\/ijms21062075","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10485_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1515\/bmc-2013-0038","volume":"5","author":"M Vieira","year":"2014","unstructured":"Vieira M, Saraiva MJ (2014) Transthyretin: a multifaceted protein. Biomol Concepts 5(1):45\u201354. https:\/\/doi.org\/10.1515\/bmc-2013-0038","journal-title":"Biomol Concepts"},{"issue":"1","key":"10485_CR15","first-page":"23","volume":"10","author":"BA Pfeffer","year":"2004","unstructured":"Pfeffer BA, Becerra SP, Borst DE, Wong P (2004) Expression of transthyretin and retinol-binding protein mRNAs and secretion of transthyretin by cultured monkey retinal pigment epithelium. Mol Vis 10(1):23\u201330","journal-title":"Mol Vis"},{"issue":"17\u201318","key":"10485_CR16","doi-asserted-by":"publisher","first-page":"6105","DOI":"10.1007\/s00018-021-03899-3","volume":"78","author":"J Magalh\u00e3es","year":"2021","unstructured":"Magalh\u00e3es J, Eira J, Liz MA (2021) The role of transthyretin in cell biology: impact on human pathophysiology. Cell Mol Life Sci 78(17\u201318):6105\u20136117. https:\/\/doi.org\/10.1007\/s00018-021-03899-3","journal-title":"Cell Mol Life Sci"},{"issue":"71","key":"10485_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0083-6729(05)71004-9","volume":"1","author":"J Bernal","year":"2005","unstructured":"Bernal J (2005) Thyroid hormones and brain development. Vitam Horm 1(71):95\u2013122. https:\/\/doi.org\/10.1016\/S0083-6729(05)71004-9","journal-title":"Vitam Horm"},{"issue":"12","key":"10485_CR18","doi-asserted-by":"publisher","first-page":"587518","DOI":"10.3389\/fendo.2021.587518","volume":"26","author":"E Fr\u00f6hlich","year":"2021","unstructured":"Fr\u00f6hlich E, Wahl R (2021) Physiological role and use of thyroid hormone metabolites\u2014potential utility in COVID-19 patients. Front Endocrinol (Lausanne) 26(12):587518. https:\/\/doi.org\/10.3389\/fendo.2021.587518","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"10485_CR19","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1515\/CCLM.2002.223","volume":"40","author":"JA Palha","year":"2002","unstructured":"Palha JA (2002) Transthyretin as a thyroid hormone carrier: function revisited. Clin Chem Lab Med 40(12):1292\u20131300. https:\/\/doi.org\/10.1515\/CCLM.2002.223","journal-title":"Clin Chem Lab Med"},{"issue":"33","key":"10485_CR20","doi-asserted-by":"publisher","first-page":"5029","DOI":"10.1021\/acs.biochem.8b00517","volume":"57","author":"P Mangrolia","year":"2018","unstructured":"Mangrolia P, Murphy RM (2018) Retinol-binding protein interferes with transthyretin-mediated \u03b2-amyloid aggregation inhibition. Biochemistry 57(33):5029\u20135040. https:\/\/doi.org\/10.1021\/acs.biochem.8b00517","journal-title":"Biochemistry"},{"issue":"12","key":"10485_CR21","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1021\/cb100144v","volume":"5","author":"SJ Hyung","year":"2010","unstructured":"Hyung SJ, Deroo S, Robinson CV (2010) Retinol and retinol-binding proteins stabilize transthyretin via the formation of retinol transport complex. ACS Chem Biol 5(12):1137\u20131146. https:\/\/doi.org\/10.1021\/cb100144v","journal-title":"ACS Chem Biol"},{"issue":"3","key":"10485_CR22","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.nlm.2007.07.006","volume":"88","author":"JC Sousa","year":"2007","unstructured":"Sousa JC, Marques F, Dias-Ferreira E, Cerqueira JJ, Sousa N, Palha JA (2007) Transthyretin influences spatial reference memory. Neurobiol Learn Mem 88(3):381\u2013385. https:\/\/doi.org\/10.1016\/j.nlm.2007.07.006","journal-title":"Neurobiol Learn Mem"},{"issue":"6","key":"10485_CR23","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1073\/pnas.90.6.2375","volume":"90","author":"V Episkopou","year":"1993","unstructured":"Episkopou V, Maeda S, Nishiguchi S, Shimada K, Gaitanaris GA, Gottesman ME, Robertson EJ (1993) Disruption of the transthyretin gene results in mice with depressed levels of plasma retinol and thyroid hormone. Proc Natl Acad Sci 90(6):2375\u20132379. https:\/\/doi.org\/10.1073\/pnas.90.6.2375","journal-title":"Proc Natl Acad Sci"},{"issue":"8\u20139","key":"10485_CR24","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1007\/pl00000763","volume":"57","author":"ST Prigge","year":"2000","unstructured":"Prigge ST, Mains RE, Eipper BA, Amzel LM (2000) New insights into copper monooxygenases and peptide amidation: structure, mechanism and function. Cell Mol Life Sci 57(8\u20139):1236\u20131259. https:\/\/doi.org\/10.1007\/pl00000763","journal-title":"Cell Mol Life Sci"},{"issue":"7","key":"10485_CR25","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1073\/pnas.0712197105","volume":"105","author":"JN Buxbaum","year":"2008","unstructured":"Buxbaum JN, Ye Z, Reixach N, Friske L, Levy C, Das P, Golde T, Masliah E, Roberts AR, Bartfai T (2008) Transthyretin protects Alzheimer\u2019s mice from the behavioral and biochemical effects of A\u03b2 toxicity. Proc Natl Acad Sci 105(7):2681\u20132686. https:\/\/doi.org\/10.1073\/pnas.0712197105","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"10485_CR26","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/j.1471-4159.2007.04828.x","volume":"103","author":"CE Fleming","year":"2007","unstructured":"Fleming CE, Saraiva MJ, Sousa MM (2007) Transthyretin enhances nerve regeneration. J Neurochem 103(2):831\u2013839. https:\/\/doi.org\/10.1111\/j.1471-4159.2007.04828.x","journal-title":"J Neurochem"},{"issue":"10","key":"10485_CR27","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1523\/JNEUROSCI.6012-08.2009","volume":"29","author":"CE Fleming","year":"2009","unstructured":"Fleming CE, Mar FM, Franquinho F, Saraiva MJ, Sousa MM (2009) Transthyretin internalization by sensory neurons is megalin mediated and necessary for its neuritogenic activity. J Neurosci 29(10):3220\u20133232. https:\/\/doi.org\/10.1523\/JNEUROSCI.6012-08.2009","journal-title":"J Neurosci"},{"issue":"7","key":"10485_CR28","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/cns.12707","volume":"23","author":"M Alemi","year":"2017","unstructured":"Alemi M, Silva SC, Santana I, Cardoso I (2017) Transthyretin stability is critical in assisting beta amyloid clearance\u2013relevance of transthyretin stabilization in Alzheimer\u2019s disease. CNS Neurosci Ther 23(7):605\u2013619. https:\/\/doi.org\/10.1111\/cns.12707","journal-title":"CNS Neurosci Ther"},{"key":"10485_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12035-024-04442-8","volume":"27","author":"C Corino","year":"2024","unstructured":"Corino C, Aimo A, Luigetti M, Ciccone L, Ferrari Chen YF, Panichella G, Musetti V, Castiglione V, Vergaro G, Emdin M, Franzini M (2024) Tetrameric transthyretin as a protective factor against Alzheimer\u2019s disease. Mol Neurobiol 27:1. https:\/\/doi.org\/10.1007\/s12035-024-04442-8","journal-title":"Mol Neurobiol"},{"issue":"3","key":"10485_CR30","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1021\/acs.bioconjchem.4c00073","volume":"35","author":"Y Wang","year":"2024","unstructured":"Wang Y, Liu W, Sun Y, Dong X (2024) Transthyretin-penetratin: a potent fusion protein inhibitor against Alzheimer\u2019s amyloid-\u03b2 fibrillogenesis with high blood brain barrier crossing capability. Bioconjug Chem 35(3):419\u2013431. https:\/\/doi.org\/10.1021\/acs.bioconjchem.4c00073","journal-title":"Bioconjug Chem"},{"issue":"1","key":"10485_CR31","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","volume":"8","author":"D Wu","year":"2023","unstructured":"Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y (2023) The blood\u2013brain barrier: structure, regulation, and drug delivery. Signal Transduct Target Ther 8(1):217. https:\/\/doi.org\/10.1038\/s41392-023-01481-w","journal-title":"Signal Transduct Target Ther"},{"key":"10485_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5772\/63194","volume":"24","author":"I Cardoso","year":"2016","unstructured":"Cardoso I, Santos LM, Alemi M (2016) Modulating role of TTR in A\u03b2 toxicity, from health to. Explor New Find Amyloidosis 24:1. https:\/\/doi.org\/10.5772\/63194","journal-title":"Explor New Find Amyloidosis"},{"issue":"23","key":"10485_CR33","doi-asserted-by":"publisher","first-page":"9003","DOI":"10.3390\/ijms21239003","volume":"21","author":"N Zar\u0119ba","year":"2020","unstructured":"Zar\u0119ba N, Kepinska M (2020) The function of transthyretin complexes with metallothionein in Alzheimer\u2019s disease. Int J Mol Sci 21(23):9003. https:\/\/doi.org\/10.3390\/ijms21239003","journal-title":"Int J Mol Sci"},{"key":"10485_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12035-024-04442-8","volume":"27","author":"C Corino","year":"2024","unstructured":"Corino C, Aimo A, Luigetti M, Ciccone L, Ferrari Chen YF, Panichella G, Musetti V, Castiglione V, Vergaro G, Emdin M, Franzini M (2024) Tetrameric transthyretin as a protective factor against Alzheimer\u2019s disease. Mol Neurobiol 27:1. https:\/\/doi.org\/10.1007\/s12035-024-04442-8","journal-title":"Mol Neurobiol"},{"issue":"6","key":"10485_CR35","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1750-1326-6-79","volume":"23","author":"X Li","year":"2011","unstructured":"Li X, Buxbaum JN (2011) Transthyretin and the brain re-visited: is neuronal synthesis of transthyretin protective in Alzheimer\u2019s disease? Mol Neurodegener 23(6):79. https:\/\/doi.org\/10.1186\/1750-1326-6-79","journal-title":"Mol Neurodegener"},{"issue":"5","key":"10485_CR36","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/jne.12271","volume":"27","author":"B Alshehri","year":"2015","unstructured":"Alshehri B, D\u2019Souza DG, Lee JY, Petratos S, Richardson SJ (2015) The diversity of mechanisms influenced by transthyretin in neurobiology: development, disease and endocrine disruption. J Neuroendocrinol 27(5):303\u2013323. https:\/\/doi.org\/10.1111\/jne.12271","journal-title":"J Neuroendocrinol"},{"issue":"8","key":"10485_CR37","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3390\/antiox13080998","volume":"13","author":"M Fiore","year":"2024","unstructured":"Fiore M, Cambieri C, Libonati L, Moret F, D\u2019Andrea E, Di Certo MG, Passananti C, Gabanella F, Corbi N, Garibaldi M, Chimenti C (2024) Oxidative stress in transthyretin-mediated amyloidosis: an exploratory study. Antioxidants 13(8):998. https:\/\/doi.org\/10.3390\/antiox13080998","journal-title":"Antioxidants"},{"issue":"50","key":"10485_CR38","doi-asserted-by":"publisher","first-page":"19423","DOI":"10.1523\/JNEUROSCI.2561-13.2013","volume":"33","author":"X Li","year":"2013","unstructured":"Li X, Zhang X, Ladiwala AR, Du D, Yadav JK, Tessier PM, Wright PE, Kelly JW, Buxbaum JN (2013) Mechanisms of transthyretin inhibition of \u03b2-amyloid aggregation in vitro. J Neurosci 33(50):19423\u201319433. https:\/\/doi.org\/10.1523\/JNEUROSCI.2561-13.2013","journal-title":"J Neurosci"},{"key":"10485_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40120-016-0040-x","volume":"5","author":"T Coelho","year":"2016","unstructured":"Coelho T, Merlini G, Bulawa CE, Fleming JA, Judge DP, Kelly JW, Maurer MS, Plant\u00e9-Bordeneuve V, Labaudini\u00e8re R, Mundayat R, Riley S (2016) Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis. Neurol Ther 5:1\u201325. https:\/\/doi.org\/10.1007\/s40120-016-0040-x","journal-title":"Neurol Ther"},{"issue":"7","key":"10485_CR40","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1002\/pro.3396","volume":"27","author":"K Garai","year":"2018","unstructured":"Garai K, Posey AE, Li X, Buxbaum JN, Pappu RV (2018) Inhibition of amyloid beta fibril formation by monomeric human transthyretin. Protein Sci 27(7):1252\u20131261. https:\/\/doi.org\/10.1002\/pro.3396","journal-title":"Protein Sci"},{"issue":"1","key":"10485_CR41","doi-asserted-by":"publisher","first-page":"20164","DOI":"10.1038\/srep20164","volume":"6","author":"M Alemi","year":"2016","unstructured":"Alemi M, Gaiteiro C, Ribeiro CA, Santos LM, Gomes JR, Oliveira SM, Couraud PO, Weksler B, Romero I, Saraiva MJ, Cardoso I (2016) Transthyretin participates in beta-amyloid transport from the brain to the liver-involvement of the low-density lipoprotein receptor-related protein 1? Sci Rep 6(1):20164. https:\/\/doi.org\/10.1038\/srep20164","journal-title":"Sci Rep"},{"issue":"9","key":"10485_CR42","doi-asserted-by":"publisher","first-page":"747699","DOI":"10.3389\/fcell.2021.747699","volume":"8","author":"J Eira","year":"2021","unstructured":"Eira J, Magalh\u00e3es J, Macedo N, Pero ME, Misgeld T, Sousa MM, Bartolini F, Liz MA (2021) Transthyretin promotes axon growth via regulation of microtubule dynamics and tubulin acetylation. Front Cell Dev Biol 8(9):747699. https:\/\/doi.org\/10.3389\/fcell.2021.747699","journal-title":"Front Cell Dev Biol"},{"key":"10485_CR43","doi-asserted-by":"publisher","DOI":"10.1101\/2024.11.27.625664","author":"J Magalhaes","year":"2024","unstructured":"Magalhaes J, Dias V, Eira J, Novoa G, Oliveira da Silva MI, Kan YY, Dias A, Carvalho E, Santos M, Seixas AI, Coelho T (2024) Rac1 inhibition prevents axonal cytoskeleton dysfunction in transthyretin amyloid polyneuropathy. bioRxiv. https:\/\/doi.org\/10.1101\/2024.11.27.625664","journal-title":"bioRxiv"},{"issue":"11","key":"10485_CR44","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1038\/cdd.2016.64","volume":"23","author":"JR Gomes","year":"2016","unstructured":"Gomes JR, Nogueira RS, Vieira M, Santos SD, Ferraz-Nogueira JP, Relvas JB, Saraiva MJ (2016) Transthyretin provides trophic support via megalin by promoting neurite outgrowth and neuroprotection in cerebral ischemia. Cell Death Differ 23(11):1749\u20131764. https:\/\/doi.org\/10.1038\/cdd.2016.64","journal-title":"Cell Death Differ"},{"issue":"14","key":"10485_CR45","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1016\/j.febslet.2006.05.020","volume":"580","author":"FA Monteiro","year":"2006","unstructured":"Monteiro FA, Cardoso I, Sousa MM, Saraiva MJ (2006) In vitro inhibition of transthyretin aggregate-induced cytotoxicity by full and peptide derived forms of the soluble receptor for advanced glycation end products (RAGE). FEBS Lett 580(14):3451\u20133456. https:\/\/doi.org\/10.1016\/j.febslet.2006.05.020","journal-title":"FEBS Lett"},{"key":"10485_CR46","doi-asserted-by":"publisher","first-page":"6063","DOI":"10.2147\/JIR.S473895","volume":"31","author":"AK Yadav","year":"2024","unstructured":"Yadav AK, Singh NK, Singh A, Ashish A, Singh S, Rai SN, Singh SK, Singh R (2024) Investigation of serum pro-inflammatory markers and trace elements among short stature in eastern Uttar Pradesh and Bihar populations. J Inflamm Res 31:6063\u20136073. https:\/\/doi.org\/10.2147\/JIR.S473895","journal-title":"J Inflamm Res"},{"key":"10485_CR47","doi-asserted-by":"publisher","first-page":"105837","DOI":"10.1016\/j.neuint.2024.105837","volume":"21","author":"FN Eze","year":"2024","unstructured":"Eze FN (2024) Transthyretin amyloidosis: role of oxidative stress and the beneficial implications of antioxidants and nutraceutical supplementation. Neurochem Int 21:105837. https:\/\/doi.org\/10.1016\/j.neuint.2024.105837","journal-title":"Neurochem Int"},{"issue":"10","key":"10485_CR48","doi-asserted-by":"publisher","first-page":"e48042","DOI":"10.1371\/journal.pone.0048042","volume":"7","author":"W Maetzler","year":"2012","unstructured":"Maetzler W, Tian Y, Baur SM, Gauger T, Odoj B, Schmid B, Schulte C, Deuschle C, Heck S, Apel A, Melms A (2012) Serum and cerebrospinal fluid levels of transthyretin in Lewy body disorders with and without dementia. PLoS ONE 7(10):e48042. https:\/\/doi.org\/10.1371\/journal.pone.0048042","journal-title":"PLoS ONE"},{"issue":"17\u201318","key":"10485_CR49","doi-asserted-by":"publisher","first-page":"6105","DOI":"10.1007\/s00018-021-03899-3","volume":"78","author":"J Magalh\u00e3es","year":"2021","unstructured":"Magalh\u00e3es J, Eira J, Liz MA (2021) The role of transthyretin in cell biology: impact on human pathophysiology. Cell Mol Life Sci 78(17\u201318):6105\u20136117. https:\/\/doi.org\/10.1007\/s00018-021-03899-3","journal-title":"Cell Mol Life Sci"},{"key":"10485_CR50","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1007\/s12035-014-8824-4","volume":"51","author":"M Vieira","year":"2015","unstructured":"Vieira M, Gomes JR, Saraiva MJ (2015) Transthyretin induces insulin-like growth factor I nuclear translocation regulating its levels in the hippocampus. Mol Neurobiol 51:1468\u20131479. https:\/\/doi.org\/10.1007\/s12035-014-8824-4","journal-title":"Mol Neurobiol"},{"issue":"1","key":"10485_CR51","doi-asserted-by":"publisher","first-page":"43","DOI":"10.14336\/AD.2023.0608","volume":"15","author":"M Nasb","year":"2024","unstructured":"Nasb M, Tao W, Chen N (2024) Alzheimer\u2019s disease puzzle: delving into pathogenesis hypotheses. Aging Dis 15(1):43\u201373. https:\/\/doi.org\/10.14336\/AD.2023.0608","journal-title":"Aging Dis"},{"issue":"22","key":"10485_CR52","doi-asserted-by":"publisher","first-page":"8672","DOI":"10.3390\/ijms21228672","volume":"21","author":"F Saponaro","year":"2020","unstructured":"Saponaro F, Kim JH, Chiellini G (2020) Transthyretin stabilization: an emerging strategy for the treatment of Alzheimer\u2019s disease? Int J Mol Sci 21(22):8672. https:\/\/doi.org\/10.3390\/ijms21228672","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10485_CR53","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3233\/JAD-2011-110488","volume":"27","author":"SM Oliveira","year":"2011","unstructured":"Oliveira SM, Ribeiro CA, Cardoso I, Saraiva MJ (2011) Gender-dependent transthyretin modulation of brain amyloid-\u03b2 levels: evidence from a mouse model of Alzheimer\u2019s disease. J Alzheimers Dis 27(2):429\u2013439. https:\/\/doi.org\/10.3233\/JAD-2011-110488","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"10485_CR54","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3233\/JAD-131355","volume":"39","author":"CA Ribeiro","year":"2014","unstructured":"Ribeiro CA, Oliveira SM, Guido LF, Magalhaes A, Valencia G, Arsequell G, Saraiva MJ, Cardoso I (2014) Transthyretin stabilization by iododiflunisal promotes amyloid-\u03b2 peptide clearance, decreases its deposition, and ameliorates cognitive deficits in an Alzheimer\u2019s disease mouse model. J Alzheimers Dis 39(2):357\u2013370. https:\/\/doi.org\/10.3233\/JAD-131355","journal-title":"J Alzheimers Dis"},{"issue":"85","key":"10485_CR55","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.bioorg.2018.12.017","volume":"1","author":"SK Shrivastava","year":"2019","unstructured":"Shrivastava SK (2019) Biphenyl-3-oxo-1, 2, 4-triazine linked piperazine derivatives as potential cholinesterase inhibitors with anti-oxidant property to improve the learning and memory. Bioorg Chem 1(85):82\u201396. https:\/\/doi.org\/10.1016\/j.bioorg.2018.12.017","journal-title":"Bioorg Chem"},{"issue":"163","key":"10485_CR56","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejmech.2018.11.049","volume":"1","author":"P Srivastava","year":"2019","unstructured":"Srivastava P, Tripathi PN, Sharma P, Rai SN, Singh SP, Srivastava RK, Shankar S, Shrivastava SK (2019) Design and development of some phenyl benzoxazole derivatives as a potent acetylcholinesterase inhibitor with antioxidant property to enhance learning and memory. Eur J Med Chem 1(163):116\u2013135. https:\/\/doi.org\/10.1016\/j.ejmech.2018.11.049","journal-title":"Eur J Med Chem"},{"issue":"1","key":"10485_CR57","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3934\/Neuroscience.2021005","volume":"8","author":"M Calabr\u00f2","year":"2021","unstructured":"Calabr\u00f2 M, Rinaldi C, Santoro G, Crisafulli C (2021) The biological pathways of Alzheimer disease: a review. AIMS Neurosci 8(1):86. https:\/\/doi.org\/10.3934\/Neuroscience.2021005","journal-title":"AIMS Neurosci"},{"key":"10485_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12010-024-05098-9","volume":"5","author":"C Prajapati","year":"2025","unstructured":"Prajapati C, Rai SN, Singh AK, Chopade BA, Singh Y, Singh SK, Haque S, Prieto MA, Ashraf GM (2025) An update of fungal endophyte diversity and strategies for augmenting therapeutic potential of their potent metabolites: recent advancement. Appl Biochem Biotechnol 5:1\u201368. https:\/\/doi.org\/10.1007\/s12010-024-05098-9","journal-title":"Appl Biochem Biotechnol"},{"issue":"8","key":"10485_CR59","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrneurol.2015.119","volume":"11","author":"JM Tarasoff-Conway","year":"2015","unstructured":"Tarasoff-Conway JM, Carare RO, Osorio RS, Glodzik L, Butler T, Fieremans E, Axel L, Rusinek H, Nicholson C, Zlokovic BV, Frangione B (2015) Clearance systems in the brain\u2014implications for Alzheimer disease. Nat Rev Neurol 11(8):457\u2013470. https:\/\/doi.org\/10.1038\/nrneurol.2015.119","journal-title":"Nat Rev Neurol"},{"issue":"44","key":"10485_CR60","doi-asserted-by":"publisher","first-page":"45897","DOI":"10.1074\/jbc.m407668200","volume":"279","author":"J Ghiso","year":"2004","unstructured":"Ghiso J, Shayo M, Calero M, Ng D, Tomidokoro Y, Gandy S, Rostagno A, Frangione B (2004) Systemic catabolism of Alzheimer\u2019s A\u03b240 and A\u03b242. J Biol Chem 279(44):45897\u201345908. https:\/\/doi.org\/10.1074\/jbc.m407668200","journal-title":"J Biol Chem"},{"issue":"10","key":"10485_CR61","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.3390\/molecules25102439","volume":"25","author":"L Ciccone","year":"2020","unstructured":"Ciccone L, Shi C, Di Lorenzo D, Van Baelen AC, Tonali N (2020) The positive side of the Alzheimer\u2019s disease amyloid cross-interactions: the case of the A\u03b2 1\u201342 peptide with tau, TTR, CysC, and ApoA1. Molecules 25(10):2439. https:\/\/doi.org\/10.3390\/molecules25102439","journal-title":"Molecules"},{"issue":"2","key":"10485_CR62","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1042\/BJ20082090","volume":"419","author":"MA Liz","year":"2009","unstructured":"Liz MA, Fleming CE, Nunes AF, Almeida MR, Mar FM, Choe Y, Craik CS, Powers JC, Bogyo M, Sousa MM (2009) Substrate specificity of transthyretin: identification of natural substrates in the nervous system. Biochem J 419(2):467\u2013474. https:\/\/doi.org\/10.1042\/BJ20082090","journal-title":"Biochem J"},{"issue":"7","key":"10485_CR63","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1007\/s12035-020-01945-y","volume":"57","author":"PN Tripathi","year":"2020","unstructured":"Tripathi PN, Srivastava P, Sharma P, Tripathi MK, Seth A, Tripathi A, Rai SN, Singh SP, Rai SN, Singh C, Singh A, Singh MP, Singh BK (2020) Mitochondrial dysfunction: a potential therapeutic target to treat Alzheimer\u2019s disease. Mol Neurobiol 57(7):3075\u20133088. https:\/\/doi.org\/10.1007\/s12035-020-01945-y","journal-title":"Mol Neurobiol"},{"issue":"8","key":"10485_CR64","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3390\/diseases12080184","volume":"12","author":"K Ramakrishna","year":"2024","unstructured":"Ramakrishna K, Karuturi P, Siakabinga Q, Ta G, Krishnamurthy S, Singh S, Kumari S, Kumar GS, Sobhia ME, Rai SN (2024) Indole-3 carbinol and diindolylmethane mitigated \u03b2-amyloid-induced neurotoxicity and acetylcholinesterase enzyme activity: in silico, in vitro, and network pharmacology study. Diseases 12(8):184. https:\/\/doi.org\/10.3390\/diseases12080184","journal-title":"Diseases"},{"issue":"50","key":"10485_CR65","doi-asserted-by":"publisher","first-page":"19423","DOI":"10.1523\/JNEUROSCI.2561-13.2013","volume":"33","author":"X Li","year":"2013","unstructured":"Li X, Zhang X, Ladiwala AR, Du D, Yadav JK, Tessier PM, Wright PE, Kelly JW, Buxbaum JN (2013) Mechanisms of transthyretin inhibition of \u03b2-amyloid aggregation in vitro. J Neurosci 33(50):19423\u201333. https:\/\/doi.org\/10.1523\/JNEUROSCI.2561-13.2013","journal-title":"J Neurosci"},{"issue":"3","key":"10485_CR66","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1021\/acs.biomac.9b01475.s001","volume":"21","author":"SA Ghadami","year":"2020","unstructured":"Ghadami SA, Chia S, Ruggeri FS, Meisl G, Bemporad F, Habchi J, Cascella R, Dobson CM, Vendruscolo M, Knowles TP, Chiti F (2020) Transthyretin inhibits primary and secondary nucleations of amyloid-\u03b2 peptide aggregation and reduces the toxicity of its oligomers. Biomacromol 21(3):1112\u20131125. https:\/\/doi.org\/10.1021\/acs.biomac.9b01475.s001","journal-title":"Biomacromol"},{"issue":"4","key":"10485_CR67","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.3233\/JAD-160033","volume":"52","author":"X Li","year":"2016","unstructured":"Li X, Song Y, Sanders CR, Buxbaum JN (2016) Transthyretin suppresses amyloid-\u03b2 secretion by Interfering with processing of the amyloid-\u03b2 protein precursor. J Alzheimers Dis 52(4):1263\u20131275. https:\/\/doi.org\/10.3233\/JAD-160033","journal-title":"J Alzheimers Dis"},{"key":"10485_CR68","doi-asserted-by":"publisher","first-page":"8276","DOI":"10.1021\/bi101280t","volume":"49","author":"J Du","year":"2010","unstructured":"Du J, Murphy RM (2010) Characterization of the interaction of \u03b2-amyloid with transthyretin monomers and tetramers. Biochemistry 49:8276\u20138289. https:\/\/doi.org\/10.1021\/bi101280t","journal-title":"Biochemistry"},{"issue":"23","key":"10485_CR69","doi-asserted-by":"publisher","first-page":"9003","DOI":"10.3390\/ijms21239003","volume":"21","author":"N Zar\u0119ba","year":"2020","unstructured":"Zar\u0119ba N, Kepinska M (2020) The function of transthyretin complexes with metallothionein in Alzheimer\u2019s disease. Int J Mol Sci 21(23):9003. https:\/\/doi.org\/10.3390\/ijms21239003","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10485_CR70","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3233\/JAD-2009-1068","volume":"17","author":"ML Hegde","year":"2009","unstructured":"Hegde ML, Bharathi P, Suram A, Venugopal C, Jagannathan R, Poddar P, Srinivas P, Sambamurti K, Rao KJ, Scancar J, Messori L (2009) Challenges associated with metal chelation therapy in Alzheimer\u2019s disease. J Alzheimers Dis 17(3):457\u2013468. https:\/\/doi.org\/10.3233\/JAD-2009-1068","journal-title":"J Alzheimers Dis"},{"key":"10485_CR71","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3109\/13506120108993822","volume":"8","author":"Y Sekijima","year":"2001","unstructured":"Sekijima Y, Tokuda T, Kametani F et al (2001) Serum transthyretin monomer in patients with familial amyloid polyneu- ropathy. Amyloid 8:257\u2013262. https:\/\/doi.org\/10.3109\/13506120108993822","journal-title":"Amyloid"},{"key":"10485_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10408363.2024.2350379","volume":"7","author":"ZL Almeida","year":"2024","unstructured":"Almeida ZL, Vaz DC, Brito RM (2024) Transthyretin mutagenesis: impact on amyloidogenesis and disease. Crit Rev Clin Lab Sci 7:1\u201325. https:\/\/doi.org\/10.1080\/10408363.2024.2350379","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"10","key":"10485_CR73","doi-asserted-by":"publisher","first-page":"e48042","DOI":"10.1371\/journal.pone.0048042","volume":"7","author":"W Maetzler","year":"2012","unstructured":"Maetzler W, Tian Y, Baur SM, Gauger T, Odoj B, Schmid B, Schulte C, Deuschle C, Heck S, Apel A, Melms A (2012) Serum and cerebrospinal fluid levels of transthyretin in lewy body disorders with and without dementia. PLoS ONE 7(10):e48042. https:\/\/doi.org\/10.1371\/journal.pone.0048042","journal-title":"PLoS ONE"},{"issue":"6","key":"10485_CR74","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/jnc.15233","volume":"156","author":"MF Dohrn","year":"2021","unstructured":"Dohrn MF, Ihne S, Hegenbart U, Medina J, Z\u00fcchner SL, Coelho T, Hahn K (2021) Targeting transthyretin-mechanism-based treatment approaches and future perspectives in hereditary amyloidosis. J Neurochem 156(6):802\u2013818. https:\/\/doi.org\/10.1111\/jnc.15233","journal-title":"J Neurochem"},{"issue":"1","key":"10485_CR75","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13024-021-00460-5","volume":"16","author":"Y Xia","year":"2021","unstructured":"Xia Y, Prokop S, Giasson BI (2021) \u201cDon\u2019t Phos Over Tau\u201d: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer\u2019s disease and other tauopathies. Mol Neurodegener 16(1):37. https:\/\/doi.org\/10.1186\/s13024-021-00460-5","journal-title":"Mol Neurodegener"},{"issue":"3","key":"10485_CR76","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3390\/diseases11030089","volume":"11","author":"K Ramakrishna","year":"2023","unstructured":"Ramakrishna K, Nalla LV, Naresh D, Venkateswarlu K, Viswanadh MK, Nalluri BN, Chakravarthy G, Duguluri S, Singh P, Rai SN, Kumar A (2023) WNT-\u03b2 catenin signaling as a potential therapeutic target for neurodegenerative diseases: current status and future perspective. Diseases 11(3):89. https:\/\/doi.org\/10.3390\/diseases11030089","journal-title":"Diseases"},{"issue":"226","key":"10485_CR77","doi-asserted-by":"publisher","first-page":"113847","DOI":"10.1016\/j.ejmech.2021.113847","volume":"15","author":"EY Cotrina","year":"2021","unstructured":"Cotrina EY, Santos LM, Rivas J, Blasi D, Leite JP, Liz MA, Busquets MA, Planas A, Prohens R, Gimeno A, Jim\u00e9nez-Barbero J, Gales L, Llop J, Quintana J, Cardoso I, Arsequell G (2021) Targeting transthyretin in Alzheimer\u2019s disease: drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer\u2019s disease. Eur J Med Chem 15(226):113847. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113847","journal-title":"Eur J Med Chem"},{"issue":"9","key":"10485_CR78","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.3390\/jcm11092360","volume":"11","author":"RC Rimbas","year":"2022","unstructured":"Rimbas RC, Balinisteanu A, Magda SL, Visoiu SI, Ciobanu AO, Beganu E, Nicula AI, Vinereanu D (2022) New advanced imaging parameters and biomarkers-a step forward in the diagnosis and prognosis of TTR cardiomyopathy. J Clin Med 11(9):2360. https:\/\/doi.org\/10.3390\/jcm11092360","journal-title":"J Clin Med"},{"issue":"6","key":"10485_CR79","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.3390\/ijms20061287","volume":"20","author":"N Ferreira","year":"2019","unstructured":"Ferreira N, Saraiva MJ, Almeida MR (2019) Uncovering the neuroprotective mechanisms of curcumin on transthyretin amyloidosis. Int J Mol Sci 20(6):1287. https:\/\/doi.org\/10.3390\/ijms20061287","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10485_CR80","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.trci.2019.01.001","volume":"1","author":"M Boada","year":"2019","unstructured":"Boada M, L\u00f3pez O, N\u00fa\u00f1ez L, Szczepiorkowski ZM, Torres M, Grifols C, P\u00e1ez A (2019) Plasma exchange for Alzheimer\u2019s disease management by albumin replacement (AMBAR) trial: study design and progress. Alzheimer\u2019s & Dement Transl Res Clin Interv 1(5):61\u201369. https:\/\/doi.org\/10.1016\/j.trci.2019.01.001","journal-title":"Alzheimer's & Dement Transl Res Clin Interv"},{"issue":"1","key":"10485_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506120410001667458","volume":"11","author":"AL Schwarzman","year":"2004","unstructured":"Schwarzman AL, Tsiper M, Wente H, Wang A, Vitek MP, Vasiliev V, Goldgaber D (2004) Amyloidogenic and anti-amyloidogenic properties of recombinant transthyretin variants. Amyloid 11(1):1. https:\/\/doi.org\/10.1080\/13506120410001667458","journal-title":"Amyloid"},{"issue":"10","key":"10485_CR82","doi-asserted-by":"publisher","first-page":"1154594","DOI":"10.3389\/fcvm.2023.1154594","volume":"23","author":"D Tomasoni","year":"2023","unstructured":"Tomasoni D, Bonfioli GB, Aimo A, Adamo M, Canepa M, Inciardi RM, Lombardi CM, Nardi M, Pagnesi M, Riccardi M, Vergaro G (2023) Treating amyloid transthyretin cardiomyopathy: Lessons learned from clinical trials. Front Cardiovasc Med 23(10):1154594. https:\/\/doi.org\/10.3389\/fcvm.2023.1154594","journal-title":"Front Cardiovasc Med"},{"key":"10485_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2024.12.005","author":"A Masri","year":"2025","unstructured":"Masri A, Bhattacharya P, Medoff B, Ejaz AU, Elman MR, Chandrashekar P, Ives L, Santos AM, Teruya SL, Zhao Y, Huang S (2025) A multicenter study of contemporary long-term tafamidis outcomes in transthyretin amyloid cardiomyopathy. JACC: CardioOncol. https:\/\/doi.org\/10.1016\/j.jaccao.2024.12.005","journal-title":"JACC: CardioOncol"},{"issue":"26","key":"10485_CR84","doi-asserted-by":"publisher","first-page":"e38767","DOI":"10.1097\/MD.0000000000038767","volume":"103","author":"G Olatunji","year":"2024","unstructured":"Olatunji G, Kokori E, Abraham IC, Omoworare O, Olatunji D, Ezeano C, Adeoba BE, Stanley AC, Oluwatobiloba AM, Oluwademilade OB, Shimelis KM (2024) A mini-review of vutrisiran and eplontersen in hereditary transthyretin-mediated amyloidosis with polyneuropathy. Medicine 103(26):e38767. https:\/\/doi.org\/10.1097\/MD.0000000000038767","journal-title":"Medicine"},{"issue":"1","key":"10485_CR85","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/ehf2.13154","volume":"8","author":"NJ Viney","year":"2021","unstructured":"Viney NJ, Guo S, Tai LJ, Baker BF, Aghajan M, Jung SW, Yu RZ, Booten S, Murray H, Machemer T, Burel S (2021) Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data. ESC Heart Failure 8(1):652\u2013661. https:\/\/doi.org\/10.1002\/ehf2.13154","journal-title":"ESC Heart Failure"},{"issue":"9","key":"10485_CR86","doi-asserted-by":"publisher","first-page":"e45368","DOI":"10.1371\/journal.pone.0045368","volume":"7","author":"CA Ribeiro","year":"2012","unstructured":"Ribeiro CA, Saraiva MJ, Cardoso I (2012) Stability of the transthyretin molecule as a key factor in the interaction with a-beta peptide\u2013relevance in Alzheimer\u2019s disease. PLoS ONE 7(9):e45368. https:\/\/doi.org\/10.1371\/journal.pone.0045368","journal-title":"PLoS ONE"},{"key":"10485_CR87","doi-asserted-by":"publisher","first-page":"5749","DOI":"10.1021\/acs.jmedchem.7b00428","volume":"60","author":"A Gimeno","year":"2017","unstructured":"Gimeno A, Santos LM, Alemi M, Rivas J, Blasi D, Cotrina EY, Llop J, Valencia G, Cardoso I, Quintana J, Arsequell G (2017) Insights on the interaction between transthyretin and A\u03b2 in solution. A saturation transfer difference (STD) NMR analysis of the role of iododiflunisal. J Med Chem 60:5749\u201358. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b00428","journal-title":"J Med Chem"},{"issue":"1","key":"10485_CR88","doi-asserted-by":"publisher","first-page":"13672","DOI":"10.1038\/s41598-019-50071-w","volume":"9","author":"X Rios","year":"2019","unstructured":"Rios X, G\u00f3mez-Vallejo V, Mart\u00edn A, Coss\u00edo U, Morcillo M\u00c1, Alemi M, Cardoso I, Quintana J, Jim\u00e9nez-Barbero J, Cotrina EY, Valencia G (2019) Radiochemical examination of transthyretin (TTR) brain penetration assisted by iododiflunisal, a TTR tetramer stabilizer and a new candidate drug for AD. Sci Rep 9(1):13672. https:\/\/doi.org\/10.1038\/s41598-019-50071-w","journal-title":"Sci Rep"},{"issue":"3","key":"10485_CR89","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1021\/acs.bioconjchem.4c00073.s001","volume":"35","author":"Y Wang","year":"2024","unstructured":"Wang Y, Liu W, Sun Y, Dong X (2024) Transthyretin-penetratin: a potent fusion protein inhibitor against Alzheimer\u2019s amyloid-\u03b2 Fibrillogenesis with high blood brain barrier crossing capability. Bioconjug Chem 35(3):419\u2013431. https:\/\/doi.org\/10.1021\/acs.bioconjchem.4c00073.s001","journal-title":"Bioconjug Chem"},{"key":"10485_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2024.12.005","author":"A Masri","year":"2025","unstructured":"Masri A, Bhattacharya P, Medoff B, Ejaz AU, Elman MR, Chandrashekar P, Ives L, Santos AM, Teruya SL, Zhao Y, Huang S (2025) A multicenter study of contemporary long-term tafamidis outcomes in transthyretin amyloid cardiomyopathy. JACC: CardioOncol. https:\/\/doi.org\/10.1016\/j.jaccao.2024.12.005","journal-title":"JACC: CardioOncol"},{"key":"10485_CR91","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s40120-020-00208-1","volume":"9","author":"I Urits","year":"2020","unstructured":"Urits I, Swanson D, Swett MC, Patel A, Berardino K, Amgalan A, Berger AA, Kassem H, Kaye AD, Viswanath O (2020) A review of patisiran (ONPATTRO\u00ae) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis. Neurol Ther 9:301\u2013315. https:\/\/doi.org\/10.1007\/s40120-020-00208-1","journal-title":"Neurol Ther"},{"issue":"1","key":"10485_CR92","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3233\/ADR-210056","volume":"6","author":"E Eldem","year":"2022","unstructured":"Eldem E, Barve A, Sallin O, Foucras S, Annoni JM, Schmid AW, Alberi AL (2022) Salivary proteomics identifies transthyretin as a biomarker of early dementia conversion. J Alzheimer\u2019s Dis Rep 6(1):31\u201341. https:\/\/doi.org\/10.3233\/ADR-210056","journal-title":"J Alzheimer's Dis Rep"},{"key":"10485_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10072-021-05191-5","volume":"26","author":"M Araghi","year":"2021","unstructured":"Araghi M, Shipley MJ, Anand A, Mills NL, Kivimaki M, Singh-Manoux A, Tab\u00e1k A, Sabia S, Brunner EJ (2021) Serum transthyretin and risk of cognitive decline and dementia: 22-year longitudinal study. Neurol Sci 26:1\u20138. https:\/\/doi.org\/10.1007\/s10072-021-05191-5","journal-title":"Neurol Sci"},{"key":"10485_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10072-021-05191-5","volume":"26","author":"M Araghi","year":"2021","unstructured":"Araghi M, Shipley MJ, Anand A, Mills NL, Kivimaki M, Singh-Manoux A, Tab\u00e1k A, Sabia S, Brunner EJ (2021) Serum transthyretin and risk of cognitive decline and dementia: 22-year longitudinal study. Neurol Sci 26:1\u20138. https:\/\/doi.org\/10.1007\/s10072-021-05191-5","journal-title":"Neurol Sci"},{"issue":"4","key":"10485_CR95","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2217\/bmm.12.42","volume":"6","author":"AM Fagan","year":"2012","unstructured":"Fagan AM, Perrin RJ (2012) Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer\u2019s disease. Biomark Med 6(4):455\u2013476. https:\/\/doi.org\/10.2217\/bmm.12.42","journal-title":"Biomark Med"},{"issue":"1","key":"10485_CR96","doi-asserted-by":"publisher","first-page":"18691","DOI":"10.1038\/s41598-019-55318-0","volume":"9","author":"YT Tien","year":"2019","unstructured":"Tien YT, Lee WJ, Liao YC, Wang WF, Jhang KM, Wang SJ, Fuh JL (2019) Plasma transthyretin as a predictor of amnestic mild cognitive impairment conversion to dementia. Sci Rep 9(1):18691. https:\/\/doi.org\/10.1038\/s41598-019-55318-0","journal-title":"Sci Rep"},{"issue":"11","key":"10485_CR97","doi-asserted-by":"publisher","first-page":"e70060","DOI":"10.1111\/cns.70060","volume":"30","author":"Y Dong","year":"2024","unstructured":"Dong Y, Song X, Wang X, Wang S, He Z (2024) The early diagnosis of Alzheimer\u2019s disease: blood-based panel biomarker discovery by proteomics and metabolomics. CNS Neurosci Ther 30(11):e70060. https:\/\/doi.org\/10.1111\/cns.70060","journal-title":"CNS Neurosci Ther"},{"issue":"10","key":"10485_CR98","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3389\/fphys.2019.00338","volume":"2","author":"RB Ibrahim","year":"2019","unstructured":"Ibrahim RB, Liu YT, Yeh SY, Tsai JW (2019) Contributions of animal models to the mechanisms and therapies of transthyretin amyloidosis. Front Physiol 2(10):338. https:\/\/doi.org\/10.3389\/fphys.2019.00338","journal-title":"Front Physiol"},{"key":"10485_CR99","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s40120-020-00208-1","volume":"9","author":"I Urits","year":"2020","unstructured":"Urits I, Swanson D, Swett MC, Patel A, Berardino K, Amgalan A, Berger AA, Kassem H, Kaye AD, Viswanath O (2020) A review of patisiran (ONPATTRO\u00ae) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis. Neurol Ther 9:301\u2013315. https:\/\/doi.org\/10.1007\/s40120-020-00208-1","journal-title":"Neurol Ther"},{"key":"10485_CR100","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/jnc.13583","volume":"139","author":"TE Golde","year":"2016","unstructured":"Golde TE (2016) Overcoming translational barriers impeding development of Alzheimer\u2019s disease modifying therapies. J Neurochem 139:224\u2013236. https:\/\/doi.org\/10.1111\/jnc.13583","journal-title":"J Neurochem"},{"key":"10485_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s42466-021-00155-8","volume":"3","author":"MF Dohrn","year":"2021","unstructured":"Dohrn MF, Medina J, Olaciregui Dague KR, Hund E (2021) Are we creating a new phenotype? Physiological barriers and ethical considerations in the treatment of hereditary transthyretin-amyloidosis. Neurol Res Pract 3:1\u20131. https:\/\/doi.org\/10.1186\/s42466-021-00155-8","journal-title":"Neurol Res Pract"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10485-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-10485-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10485-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T16:36:33Z","timestamp":1766853393000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-10485-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":101,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10485"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-10485-4","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]},"assertion":[{"value":"2 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publications"}}],"article-number":"370"}}